Chad Carr's tumor offers genetic clues for DIPG research

September 14, 2017, University of Michigan

A year and half after losing his battle against brain cancer, Chad Carr's legacy lives through research that will help other children facing the same cruel disease.

Chad, the grandson of former University of Michigan football coach Lloyd Carr, died at age 5 in 2015, 14 months after being diagnosed with the most aggressive and lethal type of brain tumor, diffuse intrinsic pontine gliomas (DIPG).

Now, Chad's donated tumor tissue is offering researchers new insight into the genetic mutations that drive DIPG to grow and progress. The first study based on his tumor appears in Nature's npj Precision Oncology.

"Typically, with a biopsy, we get a single snapshot of the genetic characteristics of the tumor. That doesn't always give you an accurate picture because each region of the tumor may be driven by different genetic changes," says lead author Carl Koshmann, M.D., a pediatric oncologist at U-M's C.S. Mott Children's Hospital.

"In this case, we were able to sequence and analyze samples from one time point from six different regions of the tumor—which gives us an incredibly rich resource of what we can learn from one DIPG. This goes much further in telling the genetic life story of the tumor."

The research, supported by Michigan Medicine's Pediatric Brain Tumor Research Initiative, establishes that a mutation in a gene known as PTEN—not previously seen as a major DIPG driver—plays an early and important role in DIPG's fatal course. The project was a result of the collaboration of DIPG research among pediatrics, neurosurgery and pathology at Michigan Medicine.

"This was Chad's final physical gift and to see that gift making a difference to DIPG research that will someday change the future for other children means so much to us," says Chad's mom Tammi Carr.

In a normal cell, the PTEN gene plays an integral role in suppressing cancer, killing off cells that aren't behaving the way they're supposed to. Any loss or mutation of the gene makes the tumor more effective.

But PTEN has not historically been considered a key driver of DIPG in children, and it remains unclear how early or "clonal" it is in the development of these tumors. Mutations that are seen throughout multiple regions in a tumor are considered to be crucial events in the earliest clusters, or clones, of cancer cells. These clonal events lead to widespread changes in the tumor that may provide ideal targets for precision medicine therapies.

Koschmann says the new data adds to multiple pieces of compelling evidence suggesting that PTEN should be considered in treatment decisions. Researchers also analyzed data from the PedcBioPortal—a national dataset of pediatric cancer genomics data—and found alterations in PTEN in up to 5 percent of DIPG cases.

This is frequent enough to show it's a recurring mutation, Koschmann says.

"PTEN has not historically been considered one of the major four mutations of DIPG. However, we found a mutation in both copies of PTEN in every single region of Chad's tumor, which was unexpected. These findings have unearthed the gene mutation's key and early role in DIPG development," says Koschmann.

"This study strengthens the case that alterations of the PTEN gene play a more influential role than was previously understood and should be included in future sequencing panels for pediatric DIPG," he adds. "If we find it, it's something we can hopefully target with precision therapy."

While some gene mutations don't yet have a drug that targets them, PTEN has been targeted in breast and prostate cancer, Koschmann says, which is why it may benefit future DIPG patients.

Sequencing Chad's 4.6-centimeter tumor in multiple regions allowed researchers to clarify how the DIPG behaved in each location of the brain and brain stem. It's an example of how this type of data can help create an "evolutionary map" of the tumor, Koschmann says.

"We are able to look at what DIPG looks like after it's been through traditional therapy and learning how the tumor grew and evaded those treatments," Koschmann says. "Studying tumor tissue in this way is like reading a textbook on how the tumor evolved after treatments and how we may potentially cut that off in the future."

Tumor tissue donations in pediatric cancer cases have historically been rare because they need to happen just hours after death. Doctors are not likely to even broach the topic with families. Michigan researchers say since the Carr story gained national attention, more families have also asked for biopsies or autopsies of tumors.

Chad's story galvanized the community, inspiring the #ChadTough movement and U-M Chad Tough Fund. This study is the first of several expected to be published as the momentum for DIPG research builds.

It's all part of Chad's legacy, Tammi Carr says.

"We knew from early on in Chad's journey that we would do whatever we could to create change, and we knew Chad would be a part of that change," she says.

"To now see all of the work that has been done in DIPG research and the discoveries that have been made, we are seeing Chad's gift having an incredible impact."

Brain tumors are the leading cause of death from childhood cancer. The most devastating type is DIPG, which stems from the region of the brain that controls breathing and heart rate. More than 90 percent of children diagnosed with DIPG die within 18 months.

"The current prognosis for DIPG remains bleak despite hundreds of previous clinical trials," Koschmann says. "A deeper molecular understanding of each individual is needed to guide therapeutic decisions.

"As we see more funding and more interest in DIPG research, we are learning more each day. The new genetic information we gain from studies like this will help us get closer to developing a new approach to treating children with what is now an incurable disease."

Explore further: New target found to attack an incurable brain tumor in children

Related Stories

New target found to attack an incurable brain tumor in children

June 6, 2017
A study published in Molecular Cancer Research reveals that a tumor suppressor gene p16 is turned off by a histone mutation (H3.3K27M), which is found in up to 70 percent of childhood brain tumors called diffuse intrinsic ...

New study on pediatric brain stem tumors

December 3, 2013
Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The ...

Going beyond genetics yields clues to challenging childhood brain cancer

November 23, 2016
Cancer is often seen as a disease of genetic changes. But one type of childhood brain tumor has stymied efforts to identify a recurring genetic defect.

PET/CT helps predict therapy effectiveness in pediatric brain tumors

May 2, 2017
Brain cancers are difficult to treat, and it can be hard to predict whether a therapy will be effective. When the patient is a child, it's even more important to predict the potential effectiveness of a drug before beginning ...

Experimental 'enhancer' drug may boost conventional therapies for deadly pediatric brain cancers

July 11, 2017
Laboratory studies suggest that an experimental drug already in early clinical trials for a variety of adult cancers might enhance radiation and chemotherapy for two childhood brain cancers that currently are virtually always ...

Potential therapy found for incurable pediatric brain cancer

November 17, 2014
Northwestern Medicine scientists have discovered a new potential drug therapy for a rare, incurable pediatric brain tumor by targeting a genetic mutation found in children with the cancer.

Recommended for you

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.